0001144204-12-023281.txt : 20120423 0001144204-12-023281.hdr.sgml : 20120423 20120423215407 ACCESSION NUMBER: 0001144204-12-023281 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120412 FILED AS OF DATE: 20120423 DATE AS OF CHANGE: 20120423 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 12774437 BUSINESS ADDRESS: STREET 1: 667 MADISON AVE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: 2123395600 MAIL ADDRESS: STREET 1: 667 MADISON AVE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 3 1 form323716_20120423095312-.xml X0205 3 2012-04-12 0 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001263508 BAKER BROS ADVISORS LLC 667 MADISON AVENUE 21ST FLOOR NEW YORK NY US 10065 1 0 1 0 Common Stock 0 I See footnotes Baker Bros. Advisors, LLC ("the Adviser") serves as the Investment Adviser to Baker Brothers Life Sciences, L.P. (direct holder of 5,077,676 shares), 14159, L.P. (direct holder of 135,739 shares), 667, L.P. (direct holder of 1,736,065 shares), Baker Bros. Investments II, L.P. (direct holder of 55,479 shares), Baker Bros. Investments, L.P. (direct holder of 165,213 shares), Baker Biotech Fund II(A), L.P. (direct holder of 100,490 shares) and Baker Tisch Investments, L.P. (direct holder of 206,799 shares) ("the Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest. On April 12, 2012, the Adviser, the Funds, and the general partners of the Funds entered into an amended and restated management agreement which gave the Adviser complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. The general partners of the Funds relinquished all discretion and authority with respect to Funds' the investments and voting power over investments. Julian C. Baker and Felix J. Baker each may be deemed to control the Adviser and to indirectly beneficially own the shares beneficially owned by it. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of these securities, except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is the beneficial owner of the above referenced securities for purposes of Section 16 or for any other purpose. The shares over which the Adviser is reporting have already been reported by Felix J. Baker and Julian C. Baker in their own Forms 3 and 4. In the future, the Adviser may jointly file Section 16 reports with Julian C. Baker and Felix J. Baker. For purposes of Section 16 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), Baker Bros. Advisors, LLC is a director by deputization by virtue of its representation on the Board of Directors of Synageva BioPharma Corp. The filing of this statement shall not be deemed an admission that the reporting person is the beneficial owner of any securities not held directly for its account for purposes of Section 16 of the Exchange Act, or otherwise. BAKER BROS. ADVISORS, LLC, Name: Scott Lessing, Title: President /s/ Scott Lessing 2012-04-23